Stories and Viewpoints

Our Impact

Learn more about NCD Alliance and TB Alliance, two of the partners that we're working with around the world.

November 18, 2021

Partnerships to help promote science, provide education and build public health literacy are core parts of our holistic approach to access and empowering people in managing their health. Today, we highlight two of our partners who have helped us reach patients around the world. 

NCD Alliance  

The NCD Alliance is a unique civil society network, dedicated to shaping a world in which everyone can live a healthy and productive life, free from the preventable suffering, stigma, disability and death caused by non-communicable diseases (NCDs). Founded in 2009, the NCD Alliance has a global network of more than 2,000 organizations in 170 countries. Together with strategic partners, including WHO, the UN, governments, development donors, philanthropies and appropriate private sector, NCDA is uniquely positioned to transform the global response to NCDs through its core functions of advocacy and accountability, capacity development, knowledge and partnerships.
Viatris has partnered with the NCD Alliance in many ways, including alongside the American College of Cardiology (ACC) and the World Heart Federation (WHF) to create the NCD Academy, a web-based, interactive educational platform for healthcare providers to improve the prevention and treatment of NCDs. The program can be downloaded worldwide at no cost, and is available on mobile and desktop devices so that primary care providers, nurses and community health workers can easily access education on various NCDs that represent the greatest contributors to global mortality.  

Viatris has also partnered with the NCD Alliance on research and content that shows the impact of the pandemic on those living with NCDs. We supported the development of a mini-documentary that highlights the intersection between COVID -19 and NCDs, as part of the “Turning the Tide” series, which focuses on the NCD epidemic. The impact of these health challenges on patients, the healthcare workforce and communities underline the need to have access to high-quality healthcare, regardless of geography or circumstance. 

“Partnership is an essential part of the NCD Alliance’s organizational DNA. The support of our partners is present in everything we do, it’s the source of our strength. We look forward to continuing our work together, to ensure everyone has an equal opportunity to enjoy the best health possible.” said Katie Dain, CEO of NCD Alliance. 

“Partnership is an essential part of the NCD Alliance’s organizational DNA. The support of our partners is present in everything we do, it’s the source of our strength. We look forward to continuing our work together, to ensure everyone has an equal opportunity to enjoy the best health possible"Katie Dain, CEO of NCD Alliance

TB Alliance 

TB Alliance is a not-for-profit organization dedicated to the discovery, development and delivery of better, faster-acting and affordable tuberculosis (TB) drugs and helping ensure that they are available to those who need them. Viatris’ collaboration with TB Alliance is a reflection of our shared commitment to ensure affordable and sustainable access to new TB treatments. 

The TB Alliance was conceived of at a meeting in South Africa in February 2000, where 120 representatives from academia, industry, major agencies, non-governmental organizations, and donors gathered to discuss the state of TB care and the need for treatments. The resulting "Declaration of Cape Town"  included the need for the creation of TB Alliance. Together with its network of partners, TB Alliance has transformed the landscape of TB drug development through the development of child-friendly treatments for drug-sensitive TB, building a robust portfolio of new TB drug candidates, and changing the way TB research is conducted. 

“All people suffering from TB must have access to innovation. That is why we are proud to partner with Viatris and leverage their deep experience in delivering quality, affordable medicines all over the world. No treatment can make a difference if it doesn’t reach people in need,” said Dr. Mel Spigelman, president and CEO, TB Alliance. 

NON-2021-5683